Compare ABUS & BHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABUS | BHK |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 815.5M | 654.4M |
| IPO Year | 2008 | N/A |
| Metric | ABUS | BHK |
|---|---|---|
| Price | $4.51 | $9.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 294.5K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.34% |
| EPS Growth | ★ 55.26 | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | ★ $14,083,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $783.24 | N/A |
| P/E Ratio | ★ N/A | $8.87 |
| Revenue Growth | ★ 128.21 | N/A |
| 52 Week Low | $2.71 | $8.94 |
| 52 Week High | $5.10 | $10.58 |
| Indicator | ABUS | BHK |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 43.80 |
| Support Level | $4.19 | $9.03 |
| Resistance Level | $4.71 | $9.72 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 68.00 | 64.52 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing, under normal market conditions, at least 75% of its managed assets in bonds that are investment-grade quality at the time of investment. The trust, under a normal market scenario, will invest in a range of bonds, including corporate bonds, U.S. government and agency securities, and mortgage-related securities.